Medicine:QazCovid-in
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Killed/Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
QazCovid-in, commercially known as QazVac,[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.[3][4] QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.[5]
Manufacturing
The vaccine can be stored at standard refrigeration temperatures (2°C-8°C) and is a two-dose régime with the doses administered twenty-one days apart.[6]The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity has been capped at 50,000 doses per month.[citation needed]
Beginning in June 2021, the vaccine is slated[7] to be packaged in large bulk to be bottled in Turkey by a major Turkish company.[8] This will allow for a production capacity of 500,000-600,000 doses per month.[9] The contract is still being negotiated,[10] despite earlier claims suggesting that the deal had already been finalized.[11][12]
In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.[13]
History
Clinical trials
In September 2020, QazVac started in Phase I/II clinical trials.[14]
In December 2020, QazVac is currently in Phase III clinical trials, which is expected to be fully completed by 9 July 2021.[2][8] It is unclear when the first preliminary results will be published.[15][12]
The administration of the vaccine for the general population began at the end of April 2021.[16] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".[8]
In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the “QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials.” [17]
Authorization
Economics
The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[citation needed] In June 2021, the capacity will increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.[18]
References
- ↑ "Kazakhstan: Officials under fire over vaccination failures" (in en). Eurasianet. 1 April 2021. https://eurasianet.org/kazakhstan-officials-under-fire-over-vaccination-failures.
- ↑ 2.0 2.1 "Vaccination with homegrown QazVac vaccine likely to start in late April" (in en). 31 March 2021. https://www.inform.kz/en/article/3770566.
- ↑ "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". 20 December 2020. https://astanatimes.com/2020/12/kazakhstan-begins-vaccinating-3000-volunteers-with-self-made-qazcovid-in/.
- ↑ Clinical trial number NCT04691908 for "Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
- ↑ "Kazakh Biosafety Research Institute Begins Clinical Trials of Another Vaccine Against COVID-19". The Astana Times. https://astanatimes.com/2021/06/kazakh-biosafety-research-institute-begins-clinical-trials-of-another-vaccine-against-covid-19/.
- ↑ "Health Minister Alexei Tsoi to be one of the first to get homegrown QazCovid-in vaccine" (in en). 26 April 2021. https://www.inform.kz/en/article/3780770.
- ↑ It's unclear at which level of preparation the vaccine will be sent to Turkey.
- ↑ 8.0 8.1 8.2 "QazVac готова и уже на подходе" (in ru). Время. 9 April 2021. https://time.kz/articles/zloba/2021/04/09/qazvac-gotova-i-uzhe-na-podhode.
- ↑ "Kazakhstan Launches Production of First Homegrown Vaccine, 'QazVac'" (in en). 25 April 2021. https://caspiannews.com/news-detail/kazakhstan-launches-production-of-first-homegrown-vaccine-qazvac-2021-4-25-0/.
- ↑ "Healthcare Ministry comments on production of QazVac vaccine" (in en). 21 April 2021. https://www.inform.kz/en/article/3779242.
- ↑ "К концу апреля в Казахстане будет выпущено 50000 доз собственной вакцины" (in ru). https://sng.today/astana/16518-k-koncu-aprelja-v-kazahstane-budet-vypuscheno-50000-doz-sobstvennoj-vakciny.html.
- ↑ 12.0 12.1 "Kazakhstan's COVID-19 vaccine to be bottled in Turkey". 10 April 2021. https://www.aa.com.tr/en/asia-pacific/kazakhstans-covid-19-vaccine-to-be-bottled-in-turkey/2204040.
- ↑ "Kazakhstan to Supply Its QazVac COVID-19 Vaccine to Other Countries Next Year". October 5, 2021. https://astanatimes.com/2021/10/kazakhstan-to-supply-its-qazvac-covid-19-vaccine-to-other-countries-next-year/.
- ↑ Clinical trial number NCT04530357 for "Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
- ↑ "3rd stage of clinical trials of QazCovid-in vaccine to be 50% complete by Apr 15" (in en). 9 April 2021. https://www.inform.kz/en/article/3774242.
- ↑ "Как правильно применять казахстанскую вакцину QazVac, рассказал ученый" (in ru). 2021-04-09. https://tengrinews.kz/news/pravilno-primenyat-kazahstanskuyu-vaktsinu-qazvac-rasskazal-434119/.
- ↑ "Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan". EClinicalMedicine 39: 101078. September 2021. doi:10.1016/j.eclinm.2021.101078. PMID 34414368.
- ↑ "Казахстанскую вакцину QazVac будут разливать в Турции" (in ru). 9 April 2021. https://informburo.kz/novosti/kazahstanskuyu-vakcinu-qaz-vac-budut-razlivat-v-turcii.
External links
 |
